Allstate Corp Buys New Stake in STERIS plc $STE

Allstate Corp purchased a new position in STERIS plc (NYSE:STE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,552 shares of the medical equipment provider’s stock, valued at approximately $879,000.

Other institutional investors have also bought and sold shares of the company. Mediolanum International Funds Ltd increased its stake in STERIS by 9.0% during the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock worth $14,883,000 after acquiring an additional 5,156 shares during the last quarter. Entropy Technologies LP boosted its holdings in shares of STERIS by 282.2% in the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after purchasing an additional 6,718 shares during the period. Vanguard Group Inc. increased its position in shares of STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after purchasing an additional 205,276 shares during the last quarter. Asset Management One Co. Ltd. increased its position in shares of STERIS by 5.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after purchasing an additional 5,072 shares during the last quarter. Finally, Cerity Partners LLC raised its holdings in STERIS by 28.8% during the 3rd quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after buying an additional 21,656 shares during the period. Institutional investors own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other news, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the transaction, the vice president owned 33,669 shares in the company, valued at approximately $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president owned 5,695 shares of the company’s stock, valued at $1,466,747.25. The trade was a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 25,044 shares of company stock valued at $6,586,218. 1.07% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Price Performance

Shares of STE stock opened at $261.16 on Thursday. The company has a market capitalization of $25.63 billion, a P/E ratio of 37.52 and a beta of 1.03. The company’s 50-day simple moving average is $258.82 and its two-hundred day simple moving average is $247.19. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the firm posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, equities analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s dividend payout ratio is currently 36.21%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.